CARDIOGRAFIN Drug Patent Profile
✉ Email this page to a colleague
When do Cardiografin patents expire, and when can generic versions of Cardiografin launch?
Cardiografin is a drug marketed by Bracco and is included in one NDA.
The generic ingredient in CARDIOGRAFIN is diatrizoate meglumine. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the diatrizoate meglumine profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CARDIOGRAFIN?
- What are the global sales for CARDIOGRAFIN?
- What is Average Wholesale Price for CARDIOGRAFIN?
Summary for CARDIOGRAFIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 992 |
| DailyMed Link: | CARDIOGRAFIN at DailyMed |
US Patents and Regulatory Information for CARDIOGRAFIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bracco | CARDIOGRAFIN | diatrizoate meglumine | INJECTABLE;INJECTION | 011620-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
